RedHill Biopharma (RDHL) Short term Debt (2022)
RedHill Biopharma (RDHL) has disclosed Short term Debt for 1 consecutive years, with $115.2 million as the latest value for Q4 2022.
- Quarterly Short term Debt changed N/A to $115.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $115.2 million through Dec 2022, changed N/A year-over-year, with the annual reading at $115.2 million for FY2022, N/A changed from the prior year.
- Short term Debt for Q4 2022 was $115.2 million at RedHill Biopharma.
- The five-year high for Short term Debt was $115.2 million in Q4 2022, with the low at $115.2 million in Q4 2022.